POM-V Prescription Required

Cevaprost 250 µg/ml Solution for Injection

Active ingredient: Cloprostenol

Form

Injection

Species

Cattle

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/5057

What it's used for

- - corpus luteum. - - - AN: 02022/2025Page 2 of 8

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Cloprostenol

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cevaprost 250 µg/ml Solution for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

-
-
corpus luteum.
-
-
-
AN: 02022/2025Page 2 of 8

AN: 02022/2025Page 5 of 8
Cattle (cows and heifers)
One dose equals 500 micrograms of cloprostenol/animal corresponding to 2 ml of the
veterinary medicinal product per animal.
Oestrus induction and synchronisation
Administer one dose per animal. When no oestrus symptoms are observed, a second
dose can be administered after 11 days.
Treatment of clinical and subclinical endometritis in the presence of a functional corpus
luteum
Administer one dose of the veterinary medicinal product per animal. If necessary, repeat
the treatment 10-14 days later.
Treatment of ovarian luteal cysts
Administer a single dose per animal
Induction of abortion up to day 150 of gestation
Administer a single dose of the veterinary medicinal product per animal, between the 5
th

and the 150
th
day of gestation .
Induction of parturition
Administer a single dose per animal not earlier than10 days before the expected date of
calving.

Do not administer the veterinary medicinal product to pregnant cows in which the
induction of abortion or parturition is not intended.
Do not administer to induce parturition in animals with suspected dystocia due to
mechanical obstruction or abnormal position, presentation and/or posture of the foetus.
Do not administer to animals with known hypersensitivity to the active substance or one
of the excipients.
Do not use in animals with compromised cardiovascular function, bronchospasm or
gastro-intestinal dysmobility. Do not administer intravenously.

Cattle (cows and heifers)
Rare
(1 to 10 animals / 10,000
animals treated)
Injection site infection
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylaxis
;
Increased respiratory rate
;
Increased heart rate
;
Abdominal pain
, Diarrhoea
3,5
;
Incoordination
;
Lying down
;
Retained placenta
, Metritis
, Dystocia
, Stillbirth
;
Restlessness, Frequent urination
3,5
;
AN: 02022/2025Page 4 of 8
May occur if anaerobic bacteria enter the injection site, especially following
intramuscular injection, and may become generalized. Aggressive antibiotic therapy,
particularly covering clostridial species, should be employed at the first sign of infection.
Careful aseptic techniques should be employed to decrease the possibility of these
infections.
Requiring immediate medical attention. Can be life-threatening.
Cloprostenol may cause effects similar to Prostaglandin
muscles.
May be caused by induction of parturition or abortion. As part of induction of
parturition, depending on the date of treatment versus the date of conception, the
incidence of placental retention may be increased.
In case of occurrence, these effects are observed within 15 minutes post-injection and
usually disappear after one hour.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

In cattle, for the termination of pregnancy, best results are obtained before day 100 of
gestation. Results are less reliable between day 100 and 150 of gestation.
There is a refractory period of four to five days after ovulation in cattle when females are
insensitive to the luteolytic effect of prostaglandins.

Special precautions for safe use in the target species:
Do not administer intravenously.
In case of oestrus induction: from the 2nd day after injection, adequate heat detection is
necessary.
Induction of parturition and abortion may cause dystocia, stillbirth and/or metritis. The
incidence of retained placenta may be increased depending on the time of treatment
relative to the date of conception.
Premature induction of farrowing will reduce the piglet’s birth weight and increase the
number of stillborn piglets and non-viable and immature born piglets. It is essential that
the mean length of gestation is calculated on each farm from past records and not to
anticipate the term of gestation by more than two days.
To reduce the risk of anaerobic infections arising from vasoconstriction at the injection
site, injections into contaminated (wet or dirty) skin areas should be. Clean and disinfect
injection sites thoroughly before administration.
All animals should receive adequate supervision after treatment. Injection into adipose
tissue can result in incomplete absorption of the veterinary medicinal product.
Cloprostenol may cause effects related to Prostaglandin activity in the smooth
muscles, such as increased frequency of urination and defecation.
AN: 02022/2025Page 3 of 8
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Prostaglandins of the F2α type, such as cloprostenol, may be absorbed through the skin
and may cause bronchospasm or miscarriage.
the product to AVOID SELF-INJECTION OR SKIN CONTACT.
Pregnant women, women of childbearing age, asthmatics and persons with other
respiratory tract diseases should avoid contact when handling this veterinary medicinal
product. Personal protective equipment consisting of disposable impervious gloves
should be worn when handling the veterinary medicinal product.
Accidental spillage on the skin should be washed immediately with soap and water. In
case of accidental self-injection or spillage onto the skin seek medical advice
immediately, particularly as shortness of breath may occur, and show the package
leaflet or label to the physician.
This veterinary medicinal product may cause hypersensitive reactions. People with
known hypersensitivity to benzyl alcohol should avoid contact with the veterinary
medicinal product.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The concomitant use of oxytocin and cloprostenol increases the effects on the uterus.
The concomitant use of progestogens decreases the effect of cloprostenol.
Do not administer the veterinary medicinal product together with non-steroidal anti-
inflammatory drugs (NSAIDS) since they inhibit endogenous prostaglandin synthesis.

Do not store above 25°C.
Keep the vial in the outer carton in order to protect from light.

Cattle:
Meat and offal: 1 day.
Milk: Zero hours.
AN: 02022/2025Page 6 of 8

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.